Inmunoterapia en cáncer : ciencia ficción convertida en realidad.
Guardado en:
2256-2877
2256-2915
4
2017-10-01
8
9
J. S. Insuasty - 2017
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
| id |
b35b23c7244c4104cf817f6c9b23f533 |
|---|---|
| record_format |
ojs |
| spelling |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7-18. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33(17):1889-94. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123-35. Fossella F, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354-62. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375(19):1823-33. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol 2016;34(21):2460-7. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-67. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. info:eu-repo/semantics/article J. S. Insuasty - 2017 http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_b239 http://purl.org/redcol/resource_type/ARTEDIT info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Catalán E, Charni S, Jaime P, Aguiló JI, Enríquez JA, Naval J, et al. MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology 2015;4(1):e985924. Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. https://creativecommons.org/licenses/by-nc-sa/4.0 Revista Colombiana de Hematología y Oncología Insuasty, J. S. editorial 4 1 Núm. 1 , Año 2017 : Octubre Artículo de revista Asociación Colombiana de Hematología y Oncología (ACHO) application/pdf https://revista.acho.info/index.php/acho/article/view/156 Español Publication Cancer immunotheraphy : science fiction that became reality. Journal article 2256-2877 2256-2915 2017-10-01 https://revista.acho.info/index.php/acho/article/download/156/131 2017-10-01T00:00:00Z 2017-10-01T00:00:00Z 10.51643/22562915.156 https://doi.org/10.51643/22562915.156 9 8 |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| spellingShingle |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. Insuasty, J. S. editorial |
| title_short |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| title_full |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| title_fullStr |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| title_full_unstemmed |
Inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| title_sort |
inmunoterapia en cáncer : ciencia ficción convertida en realidad. |
| title_eng |
Cancer immunotheraphy : science fiction that became reality. |
| author |
Insuasty, J. S. |
| author_facet |
Insuasty, J. S. |
| topicspa_str_mv |
editorial |
| topic |
editorial |
| topic_facet |
editorial |
| citationvolume |
4 |
| citationissue |
1 |
| citationedition |
Núm. 1 , Año 2017 : Octubre |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/156 |
| language |
Español |
| format |
Article |
| rights |
J. S. Insuasty - 2017 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. https://creativecommons.org/licenses/by-nc-sa/4.0 |
| references |
Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7-18. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33(17):1889-94. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123-35. Fossella F, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354-62. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375(19):1823-33. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol 2016;34(21):2460-7. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-67. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. Catalán E, Charni S, Jaime P, Aguiló JI, Enríquez JA, Naval J, et al. MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology 2015;4(1):e985924. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2017-10-01 |
| date_accessioned |
2017-10-01T00:00:00Z |
| date_available |
2017-10-01T00:00:00Z |
| url |
https://revista.acho.info/index.php/acho/article/view/156 |
| url_doi |
https://doi.org/10.51643/22562915.156 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.156 |
| citationstartpage |
8 |
| citationendpage |
9 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/156/131 |
| _version_ |
1797159675286781952 |